Treatment of sjogren's disease with nuclease fusion proteins
AssigneeResolve Therapeutics, LLC
InventorsJames Arthur Posada, Daniel Burge
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for treating Sjogren's disease by administering nuclease fusion proteins. The methods of the disclosure are useful to treat symptoms associated with Sjogren's disease, including fatigue.
Claims30
A method for treating Sjogren's disease by reducing fatigue in a human patient in need thereof, the method comprising administering an effective amount of an RNase-Fc fusion protein to the patient, thereby treating Sjogren's disease by reducing fatigue in the patient.
-6. (canceled)
(canceled)
-15. (canceled)
-20. (canceled)
-23. (canceled)
-28. (canceled)
-31. (canceled)
-36. (canceled)
The method of claim 136, wherein cognitive effects in the patient are improved by at least one point in a mental component of ProF relative to a mental component of ProF prior to treatment.
-83. (canceled)
A method of treating Sjogren's disease in a patient in need thereof, the method comprising administering an effective amount of an RNA nuclease agent to the patient, wherein treatment results in a decrease or increase in one or more inflammatory-related genes.
-90. (canceled)
A method of identifying a patient having Sjogren's disease as a candidate for treatment with an RNA nuclease agent, comprising:
- (a) determining an inflammatory-related gene expression profile in a sample obtained from the patient;
- and
- (b) comparing the inflammatory-related gene expression profile determined in step (a) with an inflammatory-related gene expression profile in a sample obtained from a suitable control subject,
- wherein the inflammatory-related gene expression profile indicates that the patient is a candidate for treatment with an RNA nuclease agent.
-106. (canceled)
Dependencies are inferred from the claim text.